Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Otorhinolaryngology

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 439 articles:
HTML format



Single Articles


    October 2025
  1. SWAIN M, Ghosh-Laskar S, McDowell L, Henson C, et al
    Patterns of care in de-novo oligo-metastatic and oligo-recurrent head and neck cancers: A Head and Neck Cancer International Group (HNCIG) Survey.
    Oral Oncol. 2025;170:107647.
    PubMed     Abstract available


  2. VARETA JA, Zhang X, Kuhnell D, Hagen MC, et al
    Characterizing the mutational landscape of sinonasal squamous cell carcinoma using whole-exome sequencing.
    Oral Oncol. 2025;169:107694.
    PubMed     Abstract available


  3. HAGREN A, Sjovall J, Brogardh C, Johansson K, et al
    Head and neck lymphedema after radiotherapy - Prevalence, changes and associated factors - a prospective observational cohort study.
    Oral Oncol. 2025;169:107671.
    PubMed     Abstract available


  4. HINTZE JM, Cleere E, Timon C, Kinsella J, et al
    The lymph node ratio is a prognostic factor for survival in laryngeal and hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107625.
    PubMed     Abstract available


  5. SIQUEIRA JM, Heguedusch D, Cunha MT, de Sousa LG, et al
    Exploring TROP2 expression in oropharyngeal squamous cell carcinoma: Association with prognosis and tumor immune microenvironment composition.
    Oral Oncol. 2025;169:107634.
    PubMed     Abstract available


  6. HOUCINE Y, Kedous S, Kamoun S, Methnani A, et al
    Nasopharyngeal low-grade papillary Adenocarcinoma: A rare entity with diagnostic challenges.
    Oral Oncol. 2025;169:107612.
    PubMed     Abstract available


  7. KUMARAGURU S, Pandiyan R
    Letter to the Editor: Clinical significance of HPV16 in oropharyngeal cancer: a commentary on recent evidence.
    Oral Oncol. 2025;169:107550.
    PubMed     Abstract available


  8. MARUDHUPANDI T
    Letter to the Editor: Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
    Oral Oncol. 2025;170:107731.
    PubMed     Abstract available


  9. MARUDHUPANDI T
    Letter to the editor: Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107730.
    PubMed     Abstract available


    September 2025
  10. MISRA SR, Das R
    Palliative care integration in head and neck Cancer: Bridging the gap between evidence and practice.
    Oral Oncol. 2025;170:107735.
    PubMed    


  11. MISRA SR, Das R, Giri M
    Commentary on "pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial".
    Oral Oncol. 2025;170:107701.
    PubMed    


  12. ANNAMALAI A
    Comments on, "Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study".
    Oral Oncol. 2025;170:107716.
    PubMed    


  13. ZHANG M
    Comment on "Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma".
    Oral Oncol. 2025;170:107722.
    PubMed    


  14. HUANG S, Liao D, Zhu X, Feng Y, et al
    Advancing oral cancer equity in India novel pathways for screening impact.
    Oral Oncol. 2025;170:107696.
    PubMed    


  15. LI M, Zhou Y, Cai M
    Letter to the Editor: Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107725.
    PubMed    


  16. MISRA SR, Das R
    Esophageal dysmotility in head and neck cancer survivors: a critical step forward and the path ahead!
    Oral Oncol. 2025;170:107718.
    PubMed    


  17. DUAN Y
    Comments on: Stroke risk after head and neck cancer diagnosis and treatment in a real-world clinical cohort.
    Oral Oncol. 2025;170:107717.
    PubMed    


  18. AL MAQRASHI ZAA, Kartolo A, Meyers BM
    Resectable locally advanced head and neck squamous cell carcinoma: cut first or immune checkpoint inhibitors first?
    Oral Oncol. 2025;170:107704.
    PubMed    


  19. CHENG H, Jiang M, Kim S, Moshiri A, et al
    Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107687.
    PubMed     Abstract available


  20. MISRA SR, Das R
    Financial instability, insurance, and transportation barriers in oral cancer care: contrasting perspectives between the United States and India.
    Oral Oncol. 2025;169:107692.
    PubMed    


  21. SAMUEL M
    Disparities in oral cancer screening in India: reflections on NFHS 5 evidence and pathways forward.
    Oral Oncol. 2025;169:107693.
    PubMed     Abstract available


  22. SINDYA J, Rajanathadurai J, Perumal E
    Reflections on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025;169:107691.
    PubMed    


  23. SASIKALA S, Sowmiya A, Usharani N
    Letter to the Editor: Salivary DNA methylation derived estimates of biological Aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2025;169:107668.
    PubMed    


  24. LUO L, Lu C, Feng H
    Refining SCCUP management: towards safe de-escalation in HPV-positive head and neck cancer-letter on Barrett et al.
    Oral Oncol. 2025;169:107681.
    PubMed    


  25. VENKATACHALAM DK, Kanimozhi K
    Letter to the Editor "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025;169:107679.
    PubMed    


  26. MISRA SR, Das R
    The imperative of careful selection and novel strategies: Comment on Mrosk et al.'s outcomes of primary chemoradiation for advanced oral cancer.
    Oral Oncol. 2025;169:107676.
    PubMed    


  27. LOVETT JT, Westra WH, Roof S, Bakst RL, et al
    Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: long-term follow-up of the quarterback de-escalation trials.
    Oral Oncol. 2025;169:107654.
    PubMed     Abstract available


  28. KUMAR GN, Sangeetha S
    Comment on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025 Sep 8:107666. doi: 10.1016/j.oraloncology.2025.107666.
    PubMed    


  29. XIAO X, Liu T, Song Y, Lu M, et al
    Evaluation on the prognostic significance of cervical occult metastasis in cN0 glottic laryngeal cancer.
    Oral Oncol. 2025;169:107648.
    PubMed    


  30. ZHANG D, Zhang J, Cai M
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107660.
    PubMed    


  31. ZHANG D, Zhang P, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107661.
    PubMed    


  32. DUAN Y
    Letter to the Editor: Oral cancer screening in India: A secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107657.
    PubMed    


  33. ZHANG D, Zhou Y, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107659.
    PubMed    


  34. MISRA SR, Das R
    Critical appraisal of "Oral cancer screening in India: A secondary analysis of disparities using national family health survey data".
    Oral Oncol. 2025;169:107653.
    PubMed    


  35. PENG X, Xie Y, Liu Y
    Comment on "Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics".
    Oral Oncol. 2025;169:107644.
    PubMed    


  36. BATOOL S, Hansen EE, Sethi RKV, Rettig EM, et al
    Financial instability, insurance, and transportation influence timely head and neck cancer care in the United States: Patient and healthcare worker perspectives.
    Oral Oncol. 2025;169:107607.
    PubMed     Abstract available


  37. DUNN LA, Ho AL, Michel LS, Wong W, et al
    A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2025;169:107524.
    PubMed     Abstract available


  38. NOEL CW, Birkenbeuel J, Ozer E, Agrawal A, et al
    Patterns of referral and outcomes in oropharyngeal cancer management.
    Oral Oncol. 2025;168:107602.
    PubMed     Abstract available


  39. GILI R, Morbini P, Bossi P
    PD-L1 Expression in head and neck squamous cell carcinoma: qualitative or quantitative assessment? Is that enough or we need something more?
    Oral Oncol. 2025;168:107606.
    PubMed     Abstract available


  40. YANG J, Wu W, Liu J, Li J, et al
    Comprehensive integration of single-cell and bulk transcriptome to reveal plasma cell heterogeneity and a prognosis signature in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;168:107595.
    PubMed     Abstract available


  41. KLEEBAYOON A, Wiwanitkit V
    Semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD): correspondence.
    Oral Oncol. 2025;169:107645.
    PubMed    


  42. BHAGIA P, Mukherjee A, Agarwal T, Giri S, et al
    Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort: Running title: Treatment in a Real-World clinical cohort.
    Oral Oncol. 2025;169:107599.
    PubMed     Abstract available


    August 2025
  43. BARRETT TF, Apicelli AJ, Ramadan S, Pipkorn P, et al
    Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation.
    Oral Oncol. 2025;169:107631.
    PubMed     Abstract available


  44. ANSARI E, Carrillo Minulina N, van Es RJJ, Dieleman FJ, et al
    Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients.
    Oral Oncol. 2025;169:107628.
    PubMed     Abstract available


  45. DAI Y, Li W
    Comment on "Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD)" by Schroter et al.
    Oral Oncol. 2025;169:107640.
    PubMed    


  46. KANA L, Chamma B, Robinette N, Cramer JD, et al
    Pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial.
    Oral Oncol. 2025;169:107633.
    PubMed     Abstract available


  47. HUANG J, Yan X, Wang S, Huang S, et al
    Improvements to the LEF Self-Management study for head and neck cancer survivors - Letter on Deng et al.
    Oral Oncol. 2025;169:107639.
    PubMed    


  48. CAO J, Han W, Liu Y
    Letter to the editor: effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;169:107624.
    PubMed    


  49. HUANG X, Gu X
    Comment on Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;169:107626.
    PubMed    


  50. MISRA SR, Das R
    Insights on: "Social health at 5 years after diagnosis in head and neck cancer Survivors".
    Oral Oncol. 2025;169:107637.
    PubMed    


  51. BOSSI P, Kiyota N, Mesia R, Rosenberg AJ, et al
    Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2025;169:107596.
    PubMed     Abstract available


  52. TANG Y, Jin Q, Gan X
    Comment on "Social health at 5 years after diagnosis of head and neck cancer".
    Oral Oncol. 2025;169:107627.
    PubMed    


  53. RAHMAN R, Sheikh I, Merchant Y, Mathur A, et al
    Oral cancer screening in India: a secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107632.
    PubMed     Abstract available


  54. DAI Y, Li WJ
    Comment on "Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial" by Deng J et al.
    Oral Oncol. 2025;169:107613.
    PubMed    


  55. CHEN Y, Yan Y
    Comment on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
    Oral Oncol. 2025;169:107614.
    PubMed    


  56. LUO R, Wu J, Zhong W, Ai K, et al
    Letter to the editor - Commentary on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
    Oral Oncol. 2025;169:107610.
    PubMed    


  57. ZHANG J, Liu DM
    Advancing self-management for head and neck cancer-related lymphedema: A promising step forward.
    Oral Oncol. 2025;169:107611.
    PubMed     Abstract available


  58. SCHROTER P, Christ LV, Dvornikovich K, Stritzke F, et al
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107604.
    PubMed     Abstract available


  59. TANG M, Dougherty M, Worona L, Ramos E, et al
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107608.
    PubMed     Abstract available


  60. COLAK G, Demir B
    Letter to the Editor: "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
    Oral Oncol. 2025;168:107579.
    PubMed    


  61. TOSONI A, Di Nunno V, Carlini A, Gatto L, et al
    The role of systemic therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma progressed to immunotherapy: A systematic review and meta analysis.
    Oral Oncol. 2025;168:107582.
    PubMed     Abstract available


  62. ASHOK A, Dimitri S, Plonowska-Hirschfeld K, Wu MP, et al
    Establishing an integrated approach to head and neck cancer treatment and prevention: The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center Model.
    Oral Oncol. 2025;168:107591.
    PubMed     Abstract available


  63. LAVANYA K, Sathishkumar K, Nallusamy D
    Letter to the editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107590.
    PubMed    


  64. HONGO T, Hirano Y, Tarutani Y, Omori H, et al
    Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
    Oral Oncol. 2025;168:107585.
    PubMed     Abstract available


  65. KOKER G, Ozcelik G
    Comment on: "Cisplatin ototoxicity and hydration schedules''.
    Oral Oncol. 2025;168:107545.
    PubMed    


  66. DENG J, Murphy BA, Andersen LP, McMenamin E, et al
    Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial.
    Oral Oncol. 2025;168:107556.
    PubMed     Abstract available


  67. SUDARSON J
    Commentary on "molecular features of T and N stage progression in laryngeal cancer".
    Oral Oncol. 2025;168:107587.
    PubMed     Abstract available


  68. YU Z, Zhuang Z, Zhao X, Chi H, et al
    Advancing AI-driven pathology in oral cancer: opportunities for enhanced TIL assessment and clinical integration.
    Oral Oncol. 2025;168:107586.
    PubMed    


  69. ASHOKKUMAR K
    Letter to the editor - a preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107580.
    PubMed    


  70. KRISHNAN M, Jothishanmugam A, Mari A, Babu S, et al
    Preserving the mandible, protecting the patient: A commentary on fracture risk following marginal mandibulectomy in head and neck cancer.
    Oral Oncol. 2025;168:107575.
    PubMed    


  71. MATSUDA Y, Fujioka-Kobayashi M, Tatsumi H, Osako-Sonoyama R, et al
    Factors associated with postoperative oral dysfunction in patients with oral cancer: a structural equation modeling study.
    Oral Oncol. 2025;168:107577.
    PubMed     Abstract available


  72. MULARONI F, Marchi F, Gaudioso P, Taboni S, et al
    Selected laryngeal squamous cell carcinomas with laryngeal mobility impairment are suitable for curative larynx-preservation treatment: A multi-institutional study on 406 patients from the ARYFIX collaborative group.
    Oral Oncol. 2025;167:107466.
    PubMed     Abstract available


  73. MORES AL, Lima de Araujo CA, de Freitas Busnardo F, Cardili L, et al
    Cutaneous metastasis of oropharyngeal squamous cell carcinoma: A case report.
    Oral Oncol. 2025;167:107438.
    PubMed     Abstract available


  74. SEDASSARI BT, Celin MF, Pigatti FM
    SMARCB1-deficient sinonasal carcinoma with oral involvement: A potential mimicker of salivary-type carcinomas.
    Oral Oncol. 2025;167:107435.
    PubMed     Abstract available


  75. TONSBEEK AM, Hundepool CA, van der Oest M, Offerman MPJ, et al
    Life following total laryngectomy: mixed-model analyses of longitudinal patient-reported outcomes in a prospective cohort.
    Oral Oncol. 2025;167:107431.
    PubMed     Abstract available


  76. PERYASSU BC, Nicolau-Neto P, da Costa EWE, Santos IC, et al
    Assessing the prognostic significance and predictive features of cervical occult metastasis in glottic laryngeal squamous cell carcinoma.
    Oral Oncol. 2025;167:107429.
    PubMed     Abstract available


  77. DOLL C, Hofmann E, Trelinska-Finger A, Heiland M, et al
    Benefit from adjuvant radiotherapy in early-stage oral cavity and oropharyngeal cancer with solitary ipsilateral lymph node metastasis - A population-based study on German cancer registry data.
    Oral Oncol. 2025;167:107384.
    PubMed     Abstract available


  78. GUZZO M, Bianchi R, Colombo S, Santamato F, et al
    Mandibular swing approach: 25 years of experience at Istituto Nazionale Tumori of Milan.
    Oral Oncol. 2025;167:107405.
    PubMed     Abstract available


  79. TONG JY, Brimanson K, Moyer K, Wolf J, et al
    Margin analysis of radical tonsillectomy specimens following transoral robotic surgery.
    Oral Oncol. 2025;167:107403.
    PubMed     Abstract available


  80. LUNA-ORTIZ K, Guillen-Hernandez GA, Cano-Valdez AM, Alvarez-Avitia MA, et al
    Poorly differentiated ceruminous adenocarcinoma of the external auditory canal: Letter to the editor.
    Oral Oncol. 2025;168:107544.
    PubMed    


  81. JENNIFER LG, Larnaudie A, Bene MC, Cocherie T, et al
    Relationships between oral microbiome and head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2025;168:107571.
    PubMed     Abstract available


  82. HUMBERT M, Perreard M, Licaj I, Bouhnik AD, et al
    Social health at 5 years after diagnosis of head and neck cancer.
    Oral Oncol. 2025;168:107567.
    PubMed     Abstract available


    July 2025
  83. ELIA A, Tirosh O, Dinstag G, Gugel L, et al
    Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics.
    Oral Oncol. 2025;168:107536.
    PubMed     Abstract available


  84. LI Y, Xiao L, Xie R
    Mitigating survival disparities in head and neck cancer: urgent need to reduce ED-based biopsy delays.
    Oral Oncol. 2025;168:107549.
    PubMed    


  85. SHARFUNNISA SH
    Letter to the editor "reframing nutritional support in head and neck cancer: insights from a prospective cohort study".
    Oral Oncol. 2025;168:107563.
    PubMed    


  86. ZHANG D, Cai M
    Letter to the Editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107558.
    PubMed    


  87. RAJASEKAR A
    Letter to the Editor: HCV infection in head and neck cancer patients: Implications for screening and prognosis in a low prevalence setting.
    Oral Oncol. 2025;168:107561.
    PubMed     Abstract available


  88. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
    Oral Oncol. 2025 Jul 27:107510. doi: 10.1016/j.oraloncology.2025.107510.
    PubMed    


  89. KRISHNAN M, Babu S
    Commentary on Lee et al: From crisis to diagnosis: redefining the emergency department's role in head and neck cancer detection.
    Oral Oncol. 2025;168:107546.
    PubMed    


  90. PENG J, Liang Z, Wang J, Wang G, et al
    Comment on effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;168:107537.
    PubMed    


  91. KRISHNAN M, Babu S
    Letter to the editor: redefining surgical paradigms in isthmic papillary thyroid carcinoma: a timely reappraisal.
    Oral Oncol. 2025;168:107562.
    PubMed    


  92. NARENKUMAR J, Parthipan P
    Letter to the Editor: Impact of the COVID-19 pandemic on diagnosis and disease stage in HPV-positive oropharyngeal cancer: insights and future directions.
    Oral Oncol. 2025;168:107541.
    PubMed     Abstract available


  93. D'ANDREA C, Marhic A, Leveque E, Thureau S, et al
    Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study.
    Oral Oncol. 2025;168:107512.
    PubMed     Abstract available


  94. BABU S, Krishnan M, Ravi PS
    "Commentary on: Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction".
    Oral Oncol. 2025;168:107552.
    PubMed    


  95. KRISHNAN M, Chawla KK, Babu S, D S, et al
    Letter to the editor: Molecular stratification in papillary thyroid carcinoma: Should RET fusions redefine aggressiveness in the post-BRAF era?
    Oral Oncol. 2025;168:107543.
    PubMed    


  96. MORCOM CR, Williams CMD, Al-Qadami G, Vieyra CP, et al
    The biological mechanisms underpinning nutritional and health-related consequences of mucositis in head and neck cancer - A review.
    Oral Oncol. 2025;168:107548.
    PubMed    


  97. ARULMOORTHY MP
    Navigating the diagnostic delay: optimizing timely biopsy and integrating NIR-based technologies for head and neck cancer.
    Oral Oncol. 2025;168:107518.
    PubMed     Abstract available


  98. SHARFUNNISA SH, Rahmathullah A
    Letter to the editor "Integrating nutritional profiling into immunotherapy: A modifiable predictor of outcomes in head and neck Cancer".
    Oral Oncol. 2025;168:107539.
    PubMed    


  99. BABU S, Solomon A, Krishnan M
    Commentary on "Massive nasal bleeding in nasopharyngeal carcinoma: Incidence, risk predictors, and survival impact".
    Oral Oncol. 2025;168:107528.
    PubMed    


  100. JEYARAJ G
    Commentary on, "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
    Oral Oncol. 2025;168:107532.
    PubMed    


  101. ABILAJI S, Parthipan P
    Letter to the Editor: Evaluating the risk-modifying effects of HSV-1 and HSV-2 on head and neck cancer in relation to tobacco, alcohol, and HPV-16.
    Oral Oncol. 2025;168:107516.
    PubMed     Abstract available


  102. CHAWLA JPS, Madan GK
    Comment on "Current status of circulating tumour DNA and circulating cell alterations in HPV-associated head and neck cancer".
    Oral Oncol. 2025;168:107526.
    PubMed    


  103. ZHU J, Xu J, Qu H, Hao J, et al
    A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107511.
    PubMed     Abstract available


  104. LEE MY, Huynh JD, Kim DD, Sunwoo JB, et al
    Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;168:107467.
    PubMed     Abstract available


  105. YANG Z, Lin B, Xie R
    Microvascular tongue reconstruction in oral cancer: Long-term functional outcomes and quality of life considerations.
    Oral Oncol. 2025;167:107490.
    PubMed    


  106. ZHANG Y, Liang R, Lai P
    Comment on "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
    Oral Oncol. 2025;167:107491.
    PubMed    


  107. JEYARAJ G
    Commentary on, "Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: Surgical and oncological outcomes.".
    Oral Oncol. 2025;167:107487.
    PubMed    


  108. RAJATHIRAJAN SD
    Commentary on, "Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study".
    Oral Oncol. 2025;167:107483.
    PubMed    


  109. JEYARAJ G
    Commentary on, "Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact.".
    Oral Oncol. 2025;167:107488.
    PubMed    


  110. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
    Corrigendum to "Massive nasal bleeding in nasopharyngeal carcinoma: incidence, risk predictors, and survival impact" [Oral Oncol. 167 (2025) 107456].
    Oral Oncol. 2025 Jul 4:107465. doi: 10.1016/j.oraloncology.2025.107465.
    PubMed    


  111. RAJATHIRAJAN SD
    Commentary on, "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors".
    Oral Oncol. 2025;167:107472.
    PubMed    


  112. HU A, Wen X, Tian J, Wang Z, et al
    RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma.
    Oral Oncol. 2025;167:107464.
    PubMed     Abstract available


  113. RIJKEN JA, de Ridder M, Devriese LA, Breimer GE, et al
    Long-term survival after multimodal treatment of sinonasal NUT carcinoma: a case report.
    Oral Oncol. 2025;166:107392.
    PubMed     Abstract available


  114. RONDI P, Mattavelli D, Rampinelli V, Schreiber A, et al
    The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2.
    Oral Oncol. 2025;166:107388.
    PubMed     Abstract available


  115. SOMAY E, Bascil S, Topkan E, Selek U, et al
    Re: "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors" by Kamel et al.
    Oral Oncol. 2025;167:107457.
    PubMed    


    June 2025
  116. MALGAVE DS, Hartman CM, Kramer JR, Richardson PA, et al
    Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study.
    Oral Oncol. 2025;167:107446.
    PubMed     Abstract available


  117. ABILAJI S, Narenkumar J
    Letter to the Editor: Enhancing early detection of HPV associated oropharyngeal cancer: a comparative study of NGS, ddPCR, and qPCR.
    Oral Oncol. 2025 Jun 27:107461. doi: 10.1016/j.oraloncology.2025.107461.
    PubMed     Abstract available


  118. EICKELSCHULTE S, Starus A, Murray DH, Keyser KA, et al
    Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
    Oral Oncol. 2025;167:107445.
    PubMed     Abstract available


  119. RAJATHIRAJAN SD
    Commentary on, "Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging".
    Oral Oncol. 2025;167:107453.
    PubMed    


  120. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
    Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact: Running title: Massive nasal bleeding in NPC.
    Oral Oncol. 2025;167:107456.
    PubMed     Abstract available


  121. DAUNGSUPAWONG H, Wiwanitkit V
    Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: Comment.
    Oral Oncol. 2025;167:107454.
    PubMed    


  122. SAMUEL CHAN SW, Amer Al Maqrashi ZA, Kim DH, Choi D, et al
    Induction chemotherapy and immunotherapy followed by chemo-radiotherapy in incurable advanced head and neck squamous cell carcinoma: A case-series.
    Oral Oncol. 2025;167:107439.
    PubMed    


  123. NGO DQ, Truong DS, Le DT, Hoang TM, et al
    Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: surgical and oncological outcomes.
    Oral Oncol. 2025;167:107406.
    PubMed     Abstract available


  124. ARAUJO M, Bouassaly J, Farshadi F, Hier M, et al
    Current status of circulating tumor DNA and circulating cell alterations in HPV-associated head and neck cancer.
    Oral Oncol. 2025;167:107417.
    PubMed     Abstract available


  125. KAMEL S, Humbert-Vidan L, Kaffey Z, Mirbahaeddin S, et al
    Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors.
    Oral Oncol. 2025;167:107337.
    PubMed     Abstract available


  126. MAK CH, Cao LM, Luo HY, Zhou K, et al
    Postoperative complications of neck dissection for head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Oral Oncol. 2025;167:107430.
    PubMed     Abstract available


  127. YANG X, Li R
    Reconsidering the prognostic value of HRQOL in head and neck cancer.
    Oral Oncol. 2025;167:107421.
    PubMed    


  128. YAN Y, Wang Z, Sun Y
    Comment on: Margins do not impact recurrence and survival in advanced laryngeal cancer-A retrospective cohort analysis.
    Oral Oncol. 2025;167:107427.
    PubMed    


  129. LIANG YJ, Luo MJ, Wen DX, Wang P, et al
    Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging.
    Oral Oncol. 2025;167:107404.
    PubMed     Abstract available


  130. KIM MJ, Koo BS, Cho KJ, Lee SH, et al
    Health-related quality-of-life assessment in patients with oropharyngeal cancer: A comparison of EQ-5D-5L and EORTC instruments.
    Oral Oncol. 2025;165:107342.
    PubMed     Abstract available


  131. GARSET-ZAMANI M, Makouei F, Agander TK, Lelkaitis G, et al
    Feasibility of 3D ultrasound for intraoperative tumor margin assessment in transoral robotic surgery for oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;165:107330.
    PubMed     Abstract available


  132. KUMARI S, Mishra S, Ali W, Singh US, et al
    Implication of circulating miRNAs as potential diagnostic biomarker in oropharyngeal squamous cell Carcinoma: Association with Human Papilloma Virus.
    Oral Oncol. 2025;165:107305.
    PubMed     Abstract available


  133. JANG HB, Lee DH, Lim SC
    Treatment outcomes of sinonasal adenoid cystic carcinoma: a single-center experience.
    Oral Oncol. 2025;165:107317.
    PubMed     Abstract available


  134. CHELVARAJAH RC, Liu Y, Su J, Abdalaty AH, et al
    Factors associated with detection of oligometastatic recurrence and outcome following definitive (Chemo)radiotherapy for oropharyngeal carcinoma.
    Oral Oncol. 2025;165:107310.
    PubMed     Abstract available


    May 2025
  135. HINTZE JM, Cleere E, Soo A, Timon C, et al
    Margins do not impact recurrence and survival in advanced laryngeal cancer - A retrospective cohort analysis.
    Oral Oncol. 2025;167:107402.
    PubMed     Abstract available


  136. BAIJU DC, Ravi J, Sarma M, Sureshan M, et al
    Detection of hotspot mutations in oral cancer through Ion AmpliSeq cancer hotspot panel v.2.0: A circulating DNA fragmentomics approach in the Northeast Indian population.
    Oral Oncol. 2025;166:107387.
    PubMed     Abstract available


  137. JEYARAJ G
    Commentary on, "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
    Oral Oncol. 2025;166:107401.
    PubMed    


  138. LIU X, Xue S
    Comment on: Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2025;166:107368.
    PubMed    


  139. VERDONCK-DE LEEUW IM, Lissenberg-Witte BI, de Bree R, Buffart LM, et al
    The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study.
    Oral Oncol. 2025;166:107367.
    PubMed     Abstract available


  140. OLSON B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, et al
    Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;166:107308.
    PubMed     Abstract available


  141. TONSBEEK AM, van der Lely JN, Bulstra L, Venema J, et al
    Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction.
    Oral Oncol. 2025;166:107363.
    PubMed     Abstract available


  142. MALI SB
    Corrigendum to "Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer" [Oral Oncol. 51 (2015) 565-569].
    Oral Oncol. 2025 May 10:107357. doi: 10.1016/j.oraloncology.2025.107357.
    PubMed    


  143. MALI SB
    Corrigendum to "RNA interference in oral cancer" [Oral Oncol. 51 (2015) e2-e3].
    Oral Oncol. 2025 May 9:107358. doi: 10.1016/j.oraloncology.2025.107358.
    PubMed    


  144. SHAIKH N, Pandey M, Manna S, Gawde J, et al
    Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy.
    Oral Oncol. 2025;165:107346.
    PubMed     Abstract available


  145. COSTANTINO A, Haughey BH, Alamoudi U, Magnuson JS, et al
    Prognostic significance of distant metastasis site at diagnosis in HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107361.
    PubMed     Abstract available


  146. ONAGA R, Enokida T, Kuno H, Hiyama T, et al
    Significance of imaging-detected extranodal extension in locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy followed by chemoradiotherapy.
    Oral Oncol. 2025;165:107351.
    PubMed     Abstract available


  147. ZHU X, Xu H, Zhao Y, Diao W, et al
    Single-cell transcriptomics reveal the effects of chemoimmunotherapy on hypopharyngeal cancer and its tumor microenvironment.
    Oral Oncol. 2025;165:107347.
    PubMed     Abstract available


  148. PEI Y, Yang Z, Mao Y, Chen X, et al
    Evolving dynamics in clinical trials for oral cancer: Trends, treatment modalities, and future directions.
    Oral Oncol. 2025;165:107333.
    PubMed     Abstract available


  149. XIAO X, Liu T, Lu M, Song Z, et al
    Comment on the role of lymph node level ratio in predicting prognosis of pN1 head and neck squamous cell carcinoma.
    Oral Oncol. 2025;165:107344.
    PubMed    


  150. CHENNAREDDY S, Chen S, Levinson C, Genden EM, et al
    Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review.
    Oral Oncol. 2025;164:107262.
    PubMed     Abstract available


  151. MARCHI F, Del Bon F, Chu F, Sampieri C, et al
    Refining prognostic subcategories in intermediate-advanced glottic cancer: A multicentric study on 637 patients treated by transoral laser microsurgery.
    Oral Oncol. 2025;164:107264.
    PubMed     Abstract available


  152. CANALI L, Russo E, Pangallo S, Bussu F, et al
    Regional disease control in nasal vestibule squamous cell carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2025;164:107270.
    PubMed     Abstract available


  153. MOTTA G, Magno C, Castagna L, De Berardinis T, et al
    Endoscope-assisted trans-oral approach (EATA) to remove a rare pleomorphic adenoma of the nasopharynx.
    Oral Oncol. 2025;164:107260.
    PubMed     Abstract available


  154. BEDDOK A, Popovtzer A, Calugaru V, Fontaine M, et al
    Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107309.
    PubMed     Abstract available


    April 2025
  155. MALI SB
    Corrigendum to "Proteomics for oral cancer" [Oral Oncol. 50(11) (2014) e67].
    Oral Oncol. 2025 Apr 30:107338. doi: 10.1016/j.oraloncology.2025.107338.
    PubMed    


  156. CITRO S, Ghiani L, Doni M, Miccolo C, et al
    HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer.
    Oral Oncol. 2025;165:107307.
    PubMed     Abstract available


  157. SILVA CUNHA JL
    Comment on "Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma".
    Oral Oncol. 2025;165:107336.
    PubMed    


  158. AL FADEL AM, Jakobsen KK, Jensen LH, Carlander AF, et al
    The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;165:107311.
    PubMed     Abstract available


  159. ARDILA CM
    Enhancing the scope and impact of photobiomodulation research in head and neck cancer therapy.
    Oral Oncol. 2025;165:107303.
    PubMed    


  160. JEYARAJ G
    Commentary on, "Molecular features of T and N stage progression in laryngeal cancer.".
    Oral Oncol. 2025;165:107331.
    PubMed    


  161. BARCELONA MVN, Waldron J, Sullivan BO, Su J, et al
    Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy.
    Oral Oncol. 2025;165:107299.
    PubMed     Abstract available


  162. YAO CMKL, Hueniken K, Huang SH, Liu G, et al
    Development of a patient reported outcomes based machine learning model to predict recurrences in head and neck cancer.
    Oral Oncol. 2025;165:107304.
    PubMed     Abstract available


  163. JEYARA G
    Commentary on, "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.".
    Oral Oncol. 2025;165:107320.
    PubMed    


  164. ZHOU P, Zhu Y, Xu B, Jiang X, et al
    Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge.
    Oral Oncol. 2025;165:107316.
    PubMed     Abstract available


  165. COSTANTINO A, Sampieri C, Haughey BH, Alamoudi U, et al
    Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107312.
    PubMed     Abstract available


  166. KOSKENNIEMI AR, Huusko T, Routila J, Jalkanen S, et al
    Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;165:107287.
    PubMed     Abstract available


  167. JEYARAJ G
    Commentary on, "Effect of Enhanced Recovery After Radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial".
    Oral Oncol. 2025;165:107302.
    PubMed    


  168. LI N, Zeng PYF, Kim HAJ, Karimi A, et al
    Molecular features of T and N stage progression in laryngeal cancer.
    Oral Oncol. 2025;165:107283.
    PubMed     Abstract available


  169. BURGER AVM, Koot MA, van Balen DEM, Schaeffers AWMA, et al
    Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.
    Oral Oncol. 2025;164:107246.
    PubMed     Abstract available


  170. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].
    Oral Oncol. 2025 Apr 11:107292. doi: 10.1016/j.oraloncology.2025.107292.
    PubMed    


  171. MA J, Brooks C, Tasoulas J, Wind LS, et al
    Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2025;164:107293.
    PubMed    


  172. SLATER NN, Herberger L, Farsi S, Rogers AL, et al
    Assessing barriers to adjuvant therapy among patients with head and neck cancer in Arkansas.
    Oral Oncol. 2025;164:107290.
    PubMed     Abstract available


  173. XIAO J, You M, Song Y, Gao R, et al
    Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.
    Oral Oncol. 2025;164:107288.
    PubMed     Abstract available


  174. VIANNA CAMOLESI GC, Prado-Pena IB, Gomez-Caamano A, Victoria-Fernandez C, et al
    Photobiomodulation for the prevention of oral side effects secondary to head and neck cancer therapy: results of a randomised, single-blind clinical trial.
    Oral Oncol. 2025;164:107266.
    PubMed     Abstract available


  175. JEYARAJ G
    Commentary on, "Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort".
    Oral Oncol. 2025;164:107285.
    PubMed    


  176. ROSING F, Plath M, Proctor T, Hofler D, et al
    Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA.
    Oral Oncol. 2025;163:107225.
    PubMed     Abstract available


    March 2025
  177. LIN N, Zhou X, Wang Y, Zhou J, et al
    Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
    Oral Oncol. 2025;164:107269.
    PubMed     Abstract available


  178. JEYARAJ G
    Commentary on, "Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study".
    Oral Oncol. 2025;163:107256.
    PubMed    


  179. ARDILA CM, Yadalam PK
    AI-driven histopathologic insights in HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107261.
    PubMed    


  180. MATHEW JM, Busca I, Baskurt Z, Giuliani M, et al
    Changes in unmet needs after treatment for head and neck cancers - A prospective longitudinal cohort study.
    Oral Oncol. 2025;163:107250.
    PubMed     Abstract available


  181. DONG Z, Wang GY, Qin GJ, Dai DY, et al
    Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study.
    Oral Oncol. 2025;163:107223.
    PubMed     Abstract available


  182. LORENZ FJ, Kharouta M, Mahase SS, Goyal N, et al
    Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Oral Oncol. 2025;163:107251.
    PubMed     Abstract available


  183. PETRELLI F, Lorini L, Paderno A, Carioli D, et al
    Treatment of primary tumor in metastatic head and neck Carcinoma: A systematic review and Meta-Analysis.
    Oral Oncol. 2025;163:107248.
    PubMed     Abstract available


  184. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107207.
    PubMed     Abstract available


  185. GAZZINI L, Festa BM, Calabrese L
    Elective neck dissection: Are we bound to outdated concepts?
    Oral Oncol. 2025;163:107245.
    PubMed    


  186. WU WJ, An PG, Liu Q, Zhang ZQ, et al
    Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis.
    Oral Oncol. 2025;162:107218.
    PubMed     Abstract available


  187. YANG F, Peng W, Wei H, Li X, et al
    Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC.
    Oral Oncol. 2025;162:107187.
    PubMed     Abstract available


  188. YE Z, Li X, Xie F, Sun J, et al
    A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma.
    Oral Oncol. 2025;162:107185.
    PubMed     Abstract available


  189. CHARLTON A, Mughal Z, Sharin F, Sahota RB, et al
    Prevalence of synchronous bilateral/contralateral tonsil carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2025;162:107180.
    PubMed     Abstract available


  190. DE VETTE SPM, van Rijn-Dekker MI, Van den Bosch L, Keijzer K, et al
    Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort.
    Oral Oncol. 2025;163:107224.
    PubMed     Abstract available


  191. MIYAGUCHI J, Shiga K, Katagiri K, Saito D, et al
    Efficacy of boron neutron capture therapy (BNCT) for patients with oral cancer.
    Oral Oncol. 2025;163:107228.
    PubMed     Abstract available


    February 2025
  192. WICZUK-WICZEWSKA M, Bernaciak J, Nogal P, Bugaj A, et al
    Squamous cell carcinoma in the posterior larynx: A rare localization of supraglottic T1 laryngeal cancer. Case report.
    Oral Oncol. 2025;163:107227.
    PubMed     Abstract available


  193. JEYARAJ G
    Letter to the editor, "Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell carcinoma: A multicenter, open-label, single-arm, phase 1b study.".
    Oral Oncol. 2025;163:107231.
    PubMed    


  194. TINO RB, Roach MA, Fuentes GD, Agrawal A, et al
    Response to recent comments on "Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy".
    Oral Oncol. 2025;162:107220.
    PubMed    


  195. MEEKER BS MO, Katragadda A, Alsavaf MB, Birkenbeuel J, et al
    Dysphagia in head and neck cancer patients with evidence of esophageal dysmotility on manometry.
    Oral Oncol. 2025;162:107219.
    PubMed     Abstract available


  196. YANG H, Sun P, Wang Y, Wang X, et al
    Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study.
    Oral Oncol. 2025;162:107211.
    PubMed     Abstract available


  197. IQBAL MS, West N, Kovarik J, Jackson M, et al
    Effective, efficient palliative radiotherapy for advanced head and neck cancer: Real world data using 25 Gy in 5 fractions.
    Oral Oncol. 2025;162:107214.
    PubMed    


  198. KHAN A, Pillay M, Bipath R, Msimang M, et al
    Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
    Oral Oncol. 2025;162:107208.
    PubMed     Abstract available


  199. MO Y, Wei Y, Liang L, Wu T, et al
    Clinical significance of post-chemoradiotherapy 2-[(18)F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study.
    Oral Oncol. 2025;161:107160.
    PubMed     Abstract available


  200. LOUBIERES C, Baudouin R, Circiu M, Couineau F, et al
    Functional and oncological outcomes of transoral laser versus robotic surgery in supraglottic squamous cell carcinoma.
    Oral Oncol. 2025;161:107178.
    PubMed     Abstract available


  201. PERSHAD AR, Ferraro T, Shaver TB, Lee E, et al
    Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer.
    Oral Oncol. 2025;161:107139.
    PubMed     Abstract available


  202. FENG ZK, Wu WB, Zou RC, Zhang JZ, et al
    Postradiotherapy nasopharyngeal necrosis with granulation mass: Insights from a multicentre study.
    Oral Oncol. 2025;161:107170.
    PubMed     Abstract available


  203. LYU SI, Fretter C, Eckel HNC, Knipper K, et al
    High expression of H2AX/gamma-H2AX is associated with distinct biological pathway alterations and shorter survival in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;161:107171.
    PubMed     Abstract available


  204. KWON JJ, Milner TD, Kurten C, Pang EH, et al
    Towards transcervical ultrasound-guided transoral robotic surgery.
    Oral Oncol. 2025;161:107167.
    PubMed     Abstract available


  205. SUCHAN M, Wuerdemann N, Wagner S, Langer C, et al
    Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2025;162:107209.
    PubMed     Abstract available


    January 2025
  206. WENGER TA, Gao J, Nurimba M, Phung PG, et al
    Palliative care utilization among head and neck cancer patients: A population-based analysis.
    Oral Oncol. 2025;162:107205.
    PubMed     Abstract available


  207. CHEN L, Fang R, Cai Z, Huang B, et al
    CD271(high) cancer stem cells regulate macrophage polarization in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;162:107181.
    PubMed     Abstract available


  208. YIN Z, Zhao H, Zhu C, Fang J, et al
    Comment on: Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2025;161:107195.
    PubMed    


  209. JIANG H, Zhou L, Zhao T, Zou G, et al
    Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report.
    Oral Oncol. 2025;161:107192.
    PubMed    


  210. JIANG H, Zhou L, Zou G, Zhang H, et al
    Synchronous papillary and medullary thyroid carcinoma with distinct genetic mutations: A case report.
    Oral Oncol. 2025;161:107191.
    PubMed    


  211. LI MH, Hu YJ, Shan HM, Gao XL, et al
    The role of lymph node level ratio in predicting prognosis and the benefits of postoperative radiotherapy in patients with pathological N1 stage head and neck squamous cell carcinoma.
    Oral Oncol. 2025;161:107193.
    PubMed     Abstract available


  212. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
    Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;161:107179.
    PubMed     Abstract available


  213. TOPKAN E, Somay E, Selek U
    Commentary on "Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF".
    Oral Oncol. 2025;161:107175.
    PubMed    


  214. SENYUREK S, Durankus NK, Selek U, Topkan E, et al
    Comment on "The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2025;161:107177.
    PubMed    


  215. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
    From infection to immortality: The role of HPV and telomerase in head and neck cancer.
    Oral Oncol. 2025;161:107169.
    PubMed     Abstract available


  216. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.
    Oral Oncol. 2025;161:107146.
    PubMed     Abstract available


  217. XU S, He J, Liu Z, Pei Y, et al
    Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;161:107161.
    PubMed     Abstract available


    December 2024
  218. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
    The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
    Oral Oncol. 2024;161:107148.
    PubMed     Abstract available


  219. LIU Y, Fu N, Liu H, Su S, et al
    Corrigendum to "Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations" [160 (2025) 107120/Article:OO_107120].
    Oral Oncol. 2024 Dec 30:107135. doi: 10.1016/j.oraloncology.2024.107135.
    PubMed    


  220. DIETRICH N, Watson E, Tadic T, Martino R, et al
    Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
    Oral Oncol. 2024;161:107132.
    PubMed     Abstract available


  221. FANG Q, Yuan J, Zhang X, Dai L, et al
    Omitting elective neck dissection in cT1/2N0 oral squamous cell carcinoma with sentinel lymph node metastasis: A prospective study.
    Oral Oncol. 2024;161:107149.
    PubMed     Abstract available


  222. PRICE JM, Garcez K, Hughes C, Lee LW, et al
    The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2024;161:107138.
    PubMed     Abstract available


  223. STRUCKMEIER AK, Gosau M, Smeets R
    Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA.
    Oral Oncol. 2024;161:107145.
    PubMed     Abstract available


  224. MEGWALU UC, Ma Y, Divi V
    Association of race and ethnicity with quality of care among head and neck cancer patients in California.
    Oral Oncol. 2024;161:107144.
    PubMed     Abstract available


  225. PACE GM, Costantino A, De Virgilio A
    Comment on "Surgical, functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal cancers: A systematic review".
    Oral Oncol. 2024;161:107142.
    PubMed    


  226. YU ST, Huang D, Xiong C, Xie R, et al
    Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports.
    Oral Oncol. 2024;161:107140.
    PubMed     Abstract available


  227. ALMEIDA ND, Yu H, Iovoli AJ, Fang M, et al
    Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months.
    Oral Oncol. 2024;160:107136.
    PubMed     Abstract available


  228. DA MOTA SANTANA LA, Dos Santos Barreto M, Santos GA, Gopalsamy RG, et al
    Comment on "Time to treatment for head and neck cancer patients decreased during the early phase of the COVID-19 pandemic".
    Oral Oncol. 2024;160:107134.
    PubMed    


  229. PRACHA SH, Shrestha S, Ryan N, Upadhaya P, et al
    Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;160:107126.
    PubMed     Abstract available


  230. LI H, Lou L, Du J, Li M, et al
    Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;160:107129.
    PubMed     Abstract available


  231. SANKAR GANESH P, Naseef Pathoor N, Kanna Gopal R
    Letter to the editor regarding, "Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2024;159:107091.
    PubMed     Abstract available


  232. BALAJI H, Aithal VU, Varghese JJ, Devaraja K, et al
    Agreement between patient-reported and clinician-rated speech and swallowing outcomes - Understanding the trend in post-operative oral cavity cancer patients.
    Oral Oncol. 2024;159:107068.
    PubMed     Abstract available


  233. BALAGURU L, Hanubal KS, Galochkina Z, Lee JH, et al
    Surgical and functional outcomes after salvage oropharyngectomy.
    Oral Oncol. 2024;159:107050.
    PubMed     Abstract available


  234. KORIC A, Chang CP, Hu S, Snyder J, et al
    Oral health-related quality of life among oropharyngeal cancer survivors.
    Oral Oncol. 2024;159:107062.
    PubMed     Abstract available


  235. BOZKURT G, Turri Zanoni M, Ferrari M, Ioppi A, et al
    Salvage surgery in nasopharyngeal Cancer: Unraveling the efficacy of transnasal endoscopic nasopharyngectomy for advanced stage recurrent tumors.
    Oral Oncol. 2024;159:107048.
    PubMed     Abstract available


  236. DANIELS KE, Awad DR, Liu SX, Mocharnuk J, et al
    Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107031.
    PubMed     Abstract available


  237. GREEN L, McDowell L, Ip F, Tapia M, et al
    Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107032.
    PubMed     Abstract available


  238. LU YT, Lin CW, Su SC, Ho YT, et al
    L48H37, a curcumin analog, suppresses matrix metalloproteinase-9 expression and activity to hamper nasopharyngeal cancer cell migration.
    Oral Oncol. 2024;159:107038.
    PubMed     Abstract available


  239. STAIBANO P, Au M, Xie M, Gupta MK, et al
    Return to work and self-reported swallowing following transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma: A retrospective cohort study.
    Oral Oncol. 2024;159:107033.
    PubMed     Abstract available


  240. MORTAJA S, Chiumenti FA, Kalaskar DM, Dwivedi RC, et al
    Surgical complications and functional outcomes of 3191 jejunal free flaps used for reconstruction of circumferential defects following head and neck cancer resections: A systematic review.
    Oral Oncol. 2024;160:107130.
    PubMed     Abstract available


    November 2024
  241. MARRET G, Lamy C, Vacher S, Cabel L, et al
    Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA.
    Oral Oncol. 2024;160:107111.
    PubMed     Abstract available


  242. JEYARAJ G
    Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
    Oral Oncol. 2024;160:107092.
    PubMed    


  243. LIU Y, Fu N, Liu H, Su S, et al
    Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2024;160:107120.
    PubMed     Abstract available


  244. YAN C, Wang R, Zhang C, Lin G, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF.
    Oral Oncol. 2024;160:107119.
    PubMed     Abstract available


  245. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
    Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
    Oral Oncol. 2024;159:107107.
    PubMed     Abstract available


  246. LI S, Zhao T, Liu N, Li Y, et al
    Global research on oral cancer: A bibliometric analysis based on 82 highly cited publications from 2014 to 2024.
    Oral Oncol. 2024;159:107094.
    PubMed     Abstract available


  247. YANG B, Dai X, Li Z, Wu Z, et al
    Noninvasive surface-enhanced Raman spectroscopy outperforms combined positive score in predicting sensitivity to neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107105.
    PubMed     Abstract available


  248. RENGASAMY G, Priya Veeraraghavan V
    Using salivary DNA methylation to predict aging, cell changes, and protein levels for assessing oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107086.
    PubMed    


  249. LEE YC, Hsin LJ, Lin WN, Fang TJ, et al
    Robot-assisted versus conventional neck dissection in head and neck cancers: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107101.
    PubMed     Abstract available


  250. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
    Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
    Oral Oncol. 2024;159:107089.
    PubMed     Abstract available


  251. LENNON SILVA CUNHA J
    In reply to "Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study".
    Oral Oncol. 2024;159:107096.
    PubMed    


  252. TOPKAN E, Somay E, Ozturk D, Selek U, et al
    Commentary on "Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions".
    Oral Oncol. 2024;159:107099.
    PubMed    


  253. SHANG K, Li T, Chen Y, Luo X, et al
    Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial.
    Oral Oncol. 2024;159:107087.
    PubMed     Abstract available


  254. COSTANTINO A, Haughey B, Alamoudi U, Magnuson JS, et al
    Challenges in treating oropharyngeal cancer in the elderly: The role of transoral surgery.
    Oral Oncol. 2024;158:106996.
    PubMed    


  255. SOLARZ P, Mackiewicz-Nartowicz H, Sinkiewicz A, Burduk P, et al
    Results of CO2 laser surgery in laryngeal papillomatosis.
    Oral Oncol. 2024;158:107004.
    PubMed     Abstract available


  256. ASHIQUE S, Houshyari M, Islam A, Pal R, et al
    The role of microbiota in nasopharyngeal cancer: Where do we stand?
    Oral Oncol. 2024;158:106982.
    PubMed     Abstract available


  257. DE SENA COSTA DE OLIVEIRA D, Cunha JLS
    Comment on: Salivary DNA methylation derived estimates of biological aging, cellular frequency, and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107097.
    PubMed    


  258. HIMANI
    Letter to the editor: Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107093.
    PubMed    


    October 2024
  259. MUTHAMIZH S, Balachandran S, Dilipan E
    Opinion on "Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107095.
    PubMed    


  260. LEHYANTI J, Even C, Fessart E, Wagner-Ballon C, et al
    Management of oligometastatic head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2024;159:107085.
    PubMed     Abstract available


  261. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
    Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2024;159:107082.
    PubMed     Abstract available


  262. KARAMCHANDANI S, Sahovaler A, Crosbie-Jones E, McGurk M, et al
    Incidence and predictive factors for positive non-sentinel lymph nodes in completion neck dissection following a positive sentinel node biopsy in early oral cancer.
    Oral Oncol. 2024;159:107081.
    PubMed    


  263. LI D, Lopez A, Shrivastava N, Chan W, et al
    Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics.
    Oral Oncol. 2024;159:107069.
    PubMed     Abstract available


  264. WU WB, Xia L, Feng ZK, Liang JL, et al
    Characteristics and treatment of epistaxis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107071.
    PubMed     Abstract available


  265. ZANG Y, Lu Y, Yu J, Dong Q, et al
    FOXP3 inhibits proliferation and migration by competitively inhibiting YAP1 in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107066.
    PubMed     Abstract available


  266. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
    Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
    Oral Oncol. 2024;159:107073.
    PubMed     Abstract available


  267. LIU C, Zhao H, Lu Y, Xia Y, et al
    Nomograms to predict occult contralateral central lymph node metastases in unilateral papillary thyroid carcinoma with ipsilateral clinical lymph node metastasis.
    Oral Oncol. 2024;159:107051.
    PubMed     Abstract available


  268. SONG Y, Zhang Y, Bai Y, Wang T, et al
    Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study.
    Oral Oncol. 2024;159:107067.
    PubMed     Abstract available


  269. AWEEDA M, Richard K, Arnaud EH, Divi V, et al
    Factors influencing lymph node yield in head and neck squamous cell carcinoma: A scoping review.
    Oral Oncol. 2024;159:107070.
    PubMed     Abstract available


  270. HE SQ, Liu GY, Yu YH, Wang L, et al
    Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.
    Oral Oncol. 2024;159:107074.
    PubMed     Abstract available


  271. LEE RH, Evans C, Alqasieer Y, Knott PD, et al
    Bite me: Can active biting during trismus therapy improve mouth opening in head and neck cancer patients?
    Oral Oncol. 2024;159:107064.
    PubMed    


  272. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
    Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107057.
    PubMed     Abstract available


  273. TANG WZ, Xu WZ, Liu TH
    Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107065.
    PubMed    


  274. YACOUB I, Qian JY, Nashed K, Youssef M, et al
    Radiation techniques and advancements in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107060.
    PubMed    


  275. GAUDIOSO P, Contro G, Taboni S, Costantino P, et al
    Intraoperative surgical navigation as a precision medicine tool in sinonasal and craniofacial oncologic surgery.
    Oral Oncol. 2024;157:106979.
    PubMed     Abstract available


  276. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
    Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2024;159:107061.
    PubMed     Abstract available


  277. AKASHANAND, Zahiruddin QS, Jena D, Ballal S, et al
    Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107063.
    PubMed     Abstract available


    September 2024
  278. LECHIEN JR
    Surgical, Functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;159:107047.
    PubMed     Abstract available


  279. KEEFE K, McCrary HC, Wei M, Mark B, et al
    Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study.
    Oral Oncol. 2024;159:107041.
    PubMed     Abstract available


  280. DHARSHINI RAJATHIRAJAN S
    Commentary on "Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients".
    Oral Oncol. 2024;159:107053.
    PubMed    


  281. LYU W, Gong J, Zhu L, Xu T, et al
    MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2024;159:107049.
    PubMed     Abstract available


  282. PRITHVIRAJ
    Comment on "Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer".
    Oral Oncol. 2024;159:107054.
    PubMed    


  283. DINESHKUMAR R
    Letter to the editor: Risk factors associated with ototoxicity in long-term survivors of nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107052.
    PubMed    


  284. VALCENKO A, Zwick A, Schneider L, Linxweiler M, et al
    The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype.
    Oral Oncol. 2024;159:107042.
    PubMed     Abstract available


  285. MIN Y, Liu X, Wei Z, Song G, et al
    Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2024;159:107028.
    PubMed     Abstract available


  286. RENGASAMY G, Priya Veeraraghavan V
    Comment on "The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-) radiotherapy".
    Oral Oncol. 2024;159:107035.
    PubMed    


  287. DHARSHINI RAJATHIRAJAN S
    Commentary on "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.".
    Oral Oncol. 2024;159:107037.
    PubMed    


  288. DHARSHINI RAJATHIRAJAN S
    Commentary on "Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients".
    Oral Oncol. 2024;159:107036.
    PubMed    


  289. VERSCHOOR CP, Santi SA, Singh R, Tharmalingam S, et al
    Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107030.
    PubMed     Abstract available


  290. PAKA LUBAMBA G, Hua Y, Bao M, Zhang G, et al
    Variant of internal jugular vein reconstruction in bilateral radical neck dissection.
    Oral Oncol. 2024;159:107015.
    PubMed     Abstract available


  291. WANG A, Xia H, Li J, Diao P, et al
    Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107016.
    PubMed     Abstract available


  292. PRITHVIRAJ T
    Commentary on "Tumor Habitat-Based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107018.
    PubMed    


  293. XIAOYU J, Baihong P, Yaozhen L, Shen C, et al
    Preoperative protective stenting of the carotid artery in severe complex head and neck cancer resection.
    Oral Oncol. 2024;158:107012.
    PubMed     Abstract available


  294. PAYNE K, Suriyanarayanan H, Brooks J, Mehanna H, et al
    Exploring the impact of intra-tumoural heterogeneity on liquid biopsy cell-free DNA methylation and copy number in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107011.
    PubMed     Abstract available


  295. ZHANG X, Zheng W, Huang S, Li H, et al
    Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models.
    Oral Oncol. 2024;158:107000.
    PubMed     Abstract available


  296. CHEN J, Cheng H, Liang Y, Lin J, et al
    The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads.
    Oral Oncol. 2024;156:106938.
    PubMed     Abstract available


    August 2024
  297. LECHIEN JR, Hans S
    Survival, Surgical, and functional outcomes of transoral laser microsurgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;158:107009.
    PubMed     Abstract available


  298. ZHAO J, Ruan X, Wei S, Zheng X, et al
    The first report of bilateral parapharyngeal lymph node metastasis from papillary thyroid carcinoma: A case report.
    Oral Oncol. 2024;158:107006.
    PubMed    


  299. YIN WJ, Mao W, Yang F, Wang MY, et al
    Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions.
    Oral Oncol. 2024;158:107001.
    PubMed     Abstract available


  300. GE Y, Liu H, Huang W, Zhu H, et al
    Immunoinhibitory effects of hypoxia-driven reprogramming of EGR1(hi) and EGR3 positive B cells in the nasopharyngeal carcinoma microenvironment.
    Oral Oncol. 2024;158:106999.
    PubMed     Abstract available


  301. T P
    Commentary on "Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/mHNSCC)".
    Oral Oncol. 2024;158:107010.
    PubMed    


  302. ZHOU X, Shao T, Jia H, Hou L, et al
    Current state, challenges, and future perspective of adaptive radiotherapy: A narrative review of nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:107008.
    PubMed     Abstract available


  303. PRASAD M
    DNA Methylation Mediated Epigenetic Silencing of PD-1 and PD-L1: Therapeutic Implications in Oral Cancer.
    Oral Oncol. 2024 Aug 23:106995. doi: 10.1016/j.oraloncology.2024.106995.
    PubMed    


  304. KNAP RABJERG H, Grau Eriksen J, Soby S
    Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107003.
    PubMed    


  305. DU F, Shao K, Yang Y, Bai X, et al
    Comparative dosimetric analysis of normal brain tissue in patients with Nasopharyngeal carcinoma at different stages after radiation therapy.
    Oral Oncol. 2024;158:106998.
    PubMed     Abstract available


  306. ALSHEIKH S, Su J, O'Sullivan B, Ringash J, et al
    The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy.
    Oral Oncol. 2024;158:107007.
    PubMed     Abstract available


  307. SUN L, Cohen RB, Dimitrios Colevas A
    Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
    Oral Oncol. 2024;158:106997.
    PubMed     Abstract available


  308. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
    Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
    Oral Oncol. 2024;158:107002.
    PubMed     Abstract available


  309. YUAN J, Wu M, Qiu L, Xu W, et al
    Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:106980.
    PubMed     Abstract available


  310. YANG R, Li R, Niu X, Zhao Y, et al
    Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.
    Oral Oncol. 2024;158:106981.
    PubMed     Abstract available


  311. HUSSEIN NI, Molina AH, Sunga GM, Amit M, et al
    Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;158:106986.
    PubMed     Abstract available


  312. PAN GS, Sun XM, Kong FF, Wang JZ, et al
    Delta magnetic resonance imaging radiomics features?based nomogram predicts long?term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106987.
    PubMed     Abstract available


  313. QIN G, Liao X, Zhang B, Su Y, et al
    An individualized immune prognostic signature in nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106985.
    PubMed     Abstract available


  314. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
    HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
    Oral Oncol. 2024;157:106983.
    PubMed     Abstract available


  315. SHIMIZU H, Kodaira T, Kiyota N, Hayashi R, et al
    Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
    Oral Oncol. 2024;157:106976.
    PubMed     Abstract available


  316. SANKAR S
    Letter to editor regarding "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression".
    Oral Oncol. 2024;157:106977.
    PubMed    


  317. SCHAEFFERS AWMA, Scholten HA, van Beers MA, Meussen BW, et al
    The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;157:106978.
    PubMed     Abstract available


    July 2024
  318. MCDOWELL L, Gough K, White I, Corry J, et al
    Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer - A narrative review.
    Oral Oncol. 2024;157:106975.
    PubMed     Abstract available


  319. DAS S, Ghosh Laskar S, V Kane S, D'Cruz AK, et al
    Adjuvant therapy for intermediate risk factors in oral cancer: Can we reach a consensus?
    Oral Oncol. 2024;157:106972.
    PubMed     Abstract available


  320. JEYARAJ G
    Letter to the editor, "Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the head and neck Cancer Registry of Japan.".
    Oral Oncol. 2024;157:106974.
    PubMed    


  321. JEYARAJ G
    Letter to the editor, "Mutation detection in saliva from oral cancer patients".
    Oral Oncol. 2024;157:106929.
    PubMed    


  322. GANESH PS, Pathoor NN, Gopal RK
    Letter to the editor regarding "Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;157:106954.
    PubMed     Abstract available


  323. LORINI L, Zigliani G, Morbini P, Salviato E, et al
    Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study).
    Oral Oncol. 2024;157:106950.
    PubMed     Abstract available


  324. JEYACHANDRAN S
    Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
    Oral Oncol. 2024;157:106973.
    PubMed     Abstract available


  325. SURESH S
    Comment on: An algorithm for standardization of tumor infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;157:106959.
    PubMed    


  326. WEN YF, Huang WJ, Chen XL, Cai HT, et al
    Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients.
    Oral Oncol. 2024;157:106963.
    PubMed     Abstract available


  327. ICHISAKA T, Sano D, Kijima N, Kawakita D, et al
    Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the Head and Neck Cancer Registry of Japan.
    Oral Oncol. 2024;157:106942.
    PubMed     Abstract available


  328. TINO R, Roach MA, Fuentes GD, Agrawal A, et al
    Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2024;157:106944.
    PubMed     Abstract available


  329. LIM CY, Ng GWY, Goh CK, Lee MKC, et al
    Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.
    Oral Oncol. 2024;157:106941.
    PubMed     Abstract available


  330. SHANMUGAM G
    Letter to the editor, "The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.".
    Oral Oncol. 2024;157:106951.
    PubMed    


  331. MEIVELU MOOVENDHAN
    "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)".
    Oral Oncol. 2024;157:106940.
    PubMed    


  332. ZENGA J, Himburg HA, Wong SJ, Kearl T, et al
    In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations.
    Oral Oncol. 2024 Jul 14:106947. doi: 10.1016/j.oraloncology.2024.106947.
    PubMed    


  333. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma".
    Oral Oncol. 2024;156:106948.
    PubMed    


  334. SHANMUGAM G
    Commentary on, "Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.".
    Oral Oncol. 2024;156:106952.
    PubMed    


  335. PIYARATHNE NS, Liyanage SN, Rasnayaka RMSGK, Hettiarachchi PVKS, et al
    A comprehensive dataset of annotated oral cavity images for diagnosis of oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;156:106946.
    PubMed     Abstract available


  336. MAHDI AGM
    Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
    Oral Oncol. 2024;156:106939.
    PubMed     Abstract available


  337. SHANMUGAM G
    Letter to the editor, "Letter to the editor, "Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.".
    Oral Oncol. 2024;156:106935.
    PubMed    


  338. ARUMUGANAINAR D, Sekaran S
    Correspondence on "Global burdens of nasopharyngeal carcinoma in children and young adults: Trends and predictions to 2040".
    Oral Oncol. 2024;156:106933.
    PubMed    


  339. GU LW, Zhang X, Zhang J, Xiao BB, et al
    The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2024;156:106928.
    PubMed     Abstract available


  340. SURESH S
    Commentary on 'Mutation detection in saliva from oral cancer patients'.
    Oral Oncol. 2024;156:106937.
    PubMed    


  341. KASIRAJAN H, Rengasamy G, Priya Veeraraghavan V
    Comment on the "Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module".
    Oral Oncol. 2024;156:106934.
    PubMed    


  342. KANNAN R
    Comments on: Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
    Oral Oncol. 2024;156:106936.
    PubMed    


  343. DAUNGSUPAWONG H, Wiwanitkit V
    Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
    Oral Oncol. 2024;156:106930.
    PubMed    


  344. LIOKATIS P, Liokati I, Obermeier K, Smolka W, et al
    Prognostic role of lymph node micrometastasis in oral and oropharyngeal cancer: A systematic review.
    Oral Oncol. 2024;154:106808.
    PubMed     Abstract available


  345. CHEN AM
    Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
    Oral Oncol. 2024;154:106850.
    PubMed     Abstract available


  346. SATHISHKUMAR K
    Letter to the editor "risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial ".
    Oral Oncol. 2024;156:106931.
    PubMed    


  347. HARIDEVAMUTHU B
    Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
    Oral Oncol. 2024;156:106913.
    PubMed    


    June 2024
  348. BENJAMIN WJ, Feng AL, Heft Neal M, Bellile E, et al
    Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer.
    Oral Oncol. 2024;156:106917.
    PubMed     Abstract available


  349. ZHAO X, Zhou Y, Peng G, Wen L, et al
    Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2024;156:106918.
    PubMed     Abstract available


  350. SARAVANAN M, Singh Carmelin D, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;156:106911.
    PubMed    


  351. POONGAVANAM SS, Behera A, Dharmalingam Jothinathan MK
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;156:106912.
    PubMed    


  352. JEYARAJ G
    Letter to the editor, "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer".
    Oral Oncol. 2024;156:106906.
    PubMed    


  353. DONG S, Bei W, Lin L, Jiang Y, et al
    Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.
    Oral Oncol. 2024;156:106908.
    PubMed     Abstract available


  354. JEYARAJ G
    Transformative impact of 3D-Printed implants and Virtual surgical planning in oral cancer reconstruction.
    Oral Oncol. 2024;156:106896.
    PubMed    


  355. SHANMUGAM G
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.".
    Oral Oncol. 2024;156:106915.
    PubMed    


  356. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
    Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;156:106894.
    PubMed     Abstract available


  357. HARIDEVAMUTHU B
    Letter to the Editor: "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral Cancer".
    Oral Oncol. 2024;155:106902.
    PubMed    


  358. MEIVELU MOOVENDHAN
    Letter to the editor, "Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2024;155:106903.
    PubMed    


  359. PRASAD M, Sekar R, Murugan R
    Letter to editor on "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;155:106899.
    PubMed    


  360. SELVI POONGAVANAM S, Behera A, Kumar Dharmalingam Jothinathan M
    Letter to the Editor, "The predictive role of PD-L1 in head and neck Cancer: A systematic review and Meta-Analysis".
    Oral Oncol. 2024;155:106904.
    PubMed    


  361. TOPKAN E, Somay E, Bascil S, Selek U, et al
    Comment on prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;155:106898.
    PubMed    


  362. HARIDEVAMUTHU B
    Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
    Oral Oncol. 2024;155:106895.
    PubMed    


  363. LEI S, Chen L, Ji P, Li K, et al
    Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040.
    Oral Oncol. 2024;155:106891.
    PubMed     Abstract available


  364. DA MOTA SANTANA LA, Simoes JMD, Santos GA, Gopalsamy RG, et al
    Comment on "Association between COVID 19 exposure and expression of malignant pathological features in oral cancer: A retrospective cohort study".
    Oral Oncol. 2024;155:106877.
    PubMed    


  365. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
    Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
    Oral Oncol. 2024;155:106874.
    PubMed     Abstract available


  366. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    Corrigendum to "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group" [Oral Oncol. 152C (2024) 106744].
    Oral Oncol. 2024 Jun 8:106887. doi: 10.1016/j.oraloncology.2024.106887.
    PubMed    


  367. PRASAD M, Murugan R
    Comment on "The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis".
    Oral Oncol. 2024;155:106890.
    PubMed    


  368. TASOULAS J, Adams GJ, Schrank TP, Agala CB, et al
    Time to treatment for head and neck cancer patients decreased during the early phase of the Covid-19 pandemic.
    Oral Oncol. 2024;155:106879.
    PubMed    


  369. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? A multi-institutional study on 366 patients from the ARYFIX collaborative group".
    Oral Oncol. 2024;155:106878.
    PubMed    


  370. BABU S, Krishnan M
    Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
    Oral Oncol. 2024;153:106824.
    PubMed    


  371. PACE GM, Costantino A, Festa BM, Spriano G, et al
    Oropharyngeal squamous cell carcinoma: Treatment (de-) intensification?
    Oral Oncol. 2024;153:106299.
    PubMed    


  372. LU HA, Wang YM, Chih Chen W, Wu CN, et al
    Post-irradiation dysbiosis in patients with nasopharyngeal carcinoma having received radiotherapy - A pilot study.
    Oral Oncol. 2024;154:106864.
    PubMed     Abstract available


  373. KRC R, Mendes W, Molitoris J, Ferris M, et al
    Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.
    Oral Oncol. 2024;154:106875.
    PubMed     Abstract available


    May 2024
  374. XU W, Qiu L, Li F, Fei Y, et al
    Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;154:106865.
    PubMed     Abstract available


  375. IMAMURA Y, Kiyota N, Tahara M, Kodaira T, et al
    Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
    Oral Oncol. 2024;154:106868.
    PubMed     Abstract available


  376. PARK R, Li J, Slebos RJC, Chaudhary R, et al
    Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;154:106866.
    PubMed     Abstract available


  377. SARAVANAN M, Carmelin DS, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;154:106858.
    PubMed    


  378. HESHAM A, David Kim D, Alshamrani Y, AlOtaibi F, et al
    The efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy in recurrent head and neck squamous cell carcinoma. Report of a case and review of the literature.
    Oral Oncol. 2024;154:106863.
    PubMed    


  379. ABBACI M, Villard A, Auperin A, Asmandar S, et al
    Ultra-fast confocal fluorescence microscopy for neck lymph node imaging in head and neck cancer.
    Oral Oncol. 2024;154:106862.
    PubMed     Abstract available


  380. YAO Y, Ouyang Q, Wang S, Li K, et al
    Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
    Oral Oncol. 2024;154:106867.
    PubMed     Abstract available


  381. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    In response to the reply on 'Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes'.
    Oral Oncol. 2024;154:106856.
    PubMed    


  382. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
    Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
    Oral Oncol. 2024;154:106855.
    PubMed     Abstract available


  383. PEZZULLA D, Re A, Ferro M, Cilla S, et al
    Lower cranial nerve palsy after hypofractionated radiotherapy in a laryngeal cancer patient: A letter to the editor.
    Oral Oncol. 2024;154:106837.
    PubMed    


  384. ALVES DA MOTA SANTANA L, Gois Floresta L, Maciel Alves EV, Ribeiro Couto G, et al
    Reply to: Comment on "Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes".
    Oral Oncol. 2024;154:106840.
    PubMed    


  385. HE S, Yu H, He L, Liu M, et al
    Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.
    Oral Oncol. 2024;154:106827.
    PubMed     Abstract available


  386. VAZQUEZ FL, Coracin FL, Arantes KLBF, Ferigatto JL, et al
    An oral cancer screening program in Brazil: Analysis of seven years of outcome after its implementation in the suburban cities of Sao Paulo.
    Oral Oncol. 2024;154:106826.
    PubMed     Abstract available


  387. DE FELICE F, Guerrero Urbano T
    Lower-neck sparing in patients with uninvolved neck nasopharyngeal carcinoma: Unquestioned benefit?
    Oral Oncol. 2024;154:106836.
    PubMed    


  388. HAN N, Zhou D, Ruan M, Yan M, et al
    Corrigendum to "Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer" [Oral Oncol. 145 (2023) 106524].
    Oral Oncol. 2024 May 9:106831. doi: 10.1016/j.oraloncology.2024.106831.
    PubMed    


  389. INVERNIZZI C, Da Silva Ribeiro Mota A, Barbe C, Bouazzi L, et al
    Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;153:106833.
    PubMed     Abstract available


  390. PADERNO A, Petrelli F, Lorini L, Capriotti V, et al
    The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;153:106799.
    PubMed     Abstract available


  391. LIU Y, Zuo ZC, Zeng XY, Ma J, et al
    Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.
    Oral Oncol. 2024;153:106834.
    PubMed     Abstract available


  392. XU Y, Xu T, Yao Q, Chen J, et al
    Individualized radiology screening for newly diagnosed nasopharyngeal carcinoma.
    Oral Oncol. 2024;153:106828.
    PubMed     Abstract available


  393. ALMANGUSH A, Makitie AA, Leivo I
    Assessment of tumor-infiltrating lymphocytes in head and neck cancer: Clinical scenarios.
    Oral Oncol. 2024;153:106829.
    PubMed    


  394. DAS R, Misra SR
    Author's reply to comment on "awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;153:106832.
    PubMed    


  395. DHARMALINGAM JOTHINATHAN MK
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106811.
    PubMed    


  396. POOJARI M, Madabhavi I, Desai S
    Extraskeletal Ewing's sarcoma of supraglottis: A rare case report.
    Oral Oncol. 2024;152:106789.
    PubMed     Abstract available


  397. MELDGAARD JUSTESEN M, Kronberg Jakobsen K, Fenger Carlander AL, Hjordt Holm Larsen M, et al
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106783.
    PubMed     Abstract available


    April 2024
  398. TONSBEEK AM, Hundepool CA, Roubos J, Rijken B, et al
    Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module.
    Oral Oncol. 2024;153:106813.
    PubMed     Abstract available


  399. MICHIKAWA C, Gleber-Netto FO, Pickering CR, Rao X, et al
    Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer.
    Oral Oncol. 2024;153:106729.
    PubMed     Abstract available


  400. FANG Q, Yuan J, Zhang X, Dai L, et al
    Oncologic and functional results between sentinel lymph node biopsy and elective neck dissection in cT1/2N0 maxillary squamous cell carcinoma.
    Oral Oncol. 2024;152:106810.
    PubMed     Abstract available


  401. YEO BSY, Lee RS, Lim NE, Tan E, et al
    Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
    Oral Oncol. 2024;152:106786.
    PubMed     Abstract available


  402. LI Y, Zhou Y, Zhao C, Liu L, et al
    The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis.
    Oral Oncol. 2024;152:106798.
    PubMed     Abstract available


  403. RAMASAMY P, Sekaran S, Ganapathy D
    Oral cancer burden in tribal populations residing in India.
    Oral Oncol. 2024;152:106801.
    PubMed    


  404. SEKAR D
    Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106800.
    PubMed    


  405. SARAVANAN M
    Comment on "Nanomedicine, an emerging therapeutic strategy for oral cancer therapy".
    Oral Oncol. 2024;152:106806.
    PubMed    


  406. RICARDO ELIAS DE MELO P, Agra Monteiro M, Henrique Rocha Aragao H, Vitoria de Araujo Lopes N, et al
    Comment on "Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;152:106802.
    PubMed    


  407. SMITH JD, Heft-Neal ME, Rosko AJ, Chepeha DB, et al
    Upfront neck dissection to guide single-modality therapy for early stage supraglottic squamous cell carcinoma.
    Oral Oncol. 2024;152:106803.
    PubMed    


  408. KONO M, Saito S, Rokugo M, Egloff AM, et al
    Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Oral Oncol. 2024;152:106795.
    PubMed     Abstract available


  409. SEGNA E, Civita F, Denaro N, Beltramini GA, et al
    Cavernous sinus metastasis in head and neck cancer: Focus on oral squamous cell cancer.
    Oral Oncol. 2024;152:106784.
    PubMed     Abstract available


  410. SIVAPERUMAL P, Ganapathy D, Kamala K
    Revolutionizing oral cancer treatment: Harnessing the potential of adaptive CARneg T cell therapy.
    Oral Oncol. 2024;152:106794.
    PubMed    


  411. RAJAKUMAR HK, Coimbatore Sathyabal V, Vivekanandam A, Nasrin Jabarulla K, et al
    Evaluation of nuclear morphometry in exfoliative cytology of buccal mucosa in patients with high risk of oral cancer.
    Oral Oncol. 2024;152:106793.
    PubMed     Abstract available


  412. SARAVANAN M
    Comment on "The microbiome and oral cancer: More questions than answers".
    Oral Oncol. 2024;152:106792.
    PubMed    


  413. ARAGAO HHR, Monteiro MA, Lopes NVA, Cunha JLS, et al
    Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
    Oral Oncol. 2024;152:106788.
    PubMed    


  414. DAS R, Misra SR, Nayak A
    Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?
    Oral Oncol. 2024;152:106790.
    PubMed    


  415. XIAO X, Shi Z, Song Z
    Comment on circulatory mitochondrial DNA as a novel biomarker for head and neck cancers.
    Oral Oncol. 2024;152:106785.
    PubMed    


  416. GASNE C, Atallah S, Dauzier E, Thariat J, et al
    Twelve years after: The french national network on rare head and neck tumours (REFCOR).
    Oral Oncol. 2024;151:106762.
    PubMed     Abstract available


  417. MALI SB
    Role of telemedicine in head neck cancer.
    Oral Oncol. 2024;151:106746.
    PubMed     Abstract available


  418. MIRIMOGHADDAM M, Bohlouli B, Lai H, Viegas S, et al
    Trends and predictors of unplanned hospitalization among oral and oropharyngeal cancer patients; an 8-year population-based study.
    Oral Oncol. 2024;151:106742.
    PubMed     Abstract available


    March 2024
  419. MEGAHED R, Prabhu AV, Mack DP, Gholami S, et al
    Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
    Oral Oncol. 2024;152:106778.
    PubMed     Abstract available


  420. LORINI L, Gili R, Salvestrini V, Morelli I, et al
    De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
    Oral Oncol. 2024;152:106768.
    PubMed     Abstract available


  421. XIROU V, Moutafi M, Bai Y, Nwe Aung T, et al
    An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;152:106750.
    PubMed     Abstract available


  422. HONG RL, Yen CJ, Lien MY, Cheng R, et al
    Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106760.
    PubMed     Abstract available


  423. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group.
    Oral Oncol. 2024;152:106744.
    PubMed     Abstract available


  424. TOYA R, Fukugawa Y, Saito T, Matsuyama T, et al
    Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
    Oral Oncol. 2024;151:106752.
    PubMed     Abstract available


  425. RUIZ-TORRES DA, Naegele S, Podury A, Wirth L, et al
    Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
    Oral Oncol. 2024;151:106761.
    PubMed     Abstract available


  426. SIMON L, Paly J, Park E, Samuels-Kalow M, et al
    Medicare dental coverage for patients with head and neck cancer: An opportunity in need of advocates.
    Oral Oncol. 2024 Mar 15:106754. doi: 10.1016/j.oraloncology.2024.106754.
    PubMed    


  427. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    Comment on "advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with Teledentistry for Better Patient Outcomes".
    Oral Oncol. 2024;151:106758.
    PubMed    


  428. RAJANATHADURAI J, Sindya J, Madar IH, Perumal E, et al
    Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
    Oral Oncol. 2024;151:106748.
    PubMed    


  429. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
    Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Oral Oncol. 2024;151:106749.
    PubMed     Abstract available


  430. FERRARO T, Pershad AR, Arora S, Lee E, et al
    The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2024;151:106743.
    PubMed     Abstract available


  431. KIM DH, Lim ST, Kim HR, Kang EJ, et al
    Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Oral Oncol. 2024;151:106739.
    PubMed     Abstract available


  432. SANTANA LADM, Floresta LG, Alves EVM, Melo LMR, et al
    Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes.
    Oral Oncol. 2024;151:106741.
    PubMed    


  433. CHEN K, Shi M, Mo S, Liu T, et al
    Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.
    Oral Oncol. 2024;151:106738.
    PubMed     Abstract available


  434. DING C, Dai DY, Luo ZK, Wang GY, et al
    Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
    Oral Oncol. 2024;151:106725.
    PubMed     Abstract available


  435. LU X, Zhang JL, Zhai X, Liu Q, et al
    A case report on a nasal and oral cavity involving large solitary fibrous tumor and comprehensive review of case literature.
    Oral Oncol. 2024;150:106715.
    PubMed     Abstract available


  436. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    PubMed     Abstract available


    February 2024
  437. VAN SCHAIK JE, van der Vegt B, Slagter-Menkema L, van der Laan BFAM, et al
    Identification of new head and neck squamous cell carcinoma molecular imaging targets.
    Oral Oncol. 2024;151:106736.
    PubMed     Abstract available


  438. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
    Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
    Oral Oncol. 2024;151:106703.
    PubMed     Abstract available


  439. AHMED AA, Sborchia M, Bye H, Roman-Escorza M, et al
    Mutation detection in saliva from oral cancer patients.
    Oral Oncol. 2024;151:106717.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.